Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPediatrics/NeonatologyColorado Rocky Mountain iNO Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy CS173ID.C

    Inhaled Nitric Oxide Therapy (for Idaho Only)

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CS173ID.C alerts

    Get alerted when Policy CS173ID.C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Applies to Idaho, including Idaho Medicaid Plus plans, and addresses coverage of inhaled nitric oxide therapy for infants and newborns.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyInhaled Nitric Oxide Therapy (for Idaho Only)
    Policy CodePolicy CS173ID.C
    Change TypeSupporting information and references update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionConfirm that the infant has failed conventional treatment, such as mechanical ventilation, before using iNO.
    SourceLink
    POLICY UPDATE CHANGES

    The Supporting Information, Clinical Evidence, and References sections were updated to reflect current information.

    ≥34 weeksMinimum gestational age for standard covered treatment
    1 yearInfancy age range
    20 ppmInitial iNO concentration
    OI >25Oxygenation-index threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    94799
    Applicable procedure code

    Medical Necessity and Coverage Criteria

    Initial or acute therapy for eligible infants

    Covered as proven and medically necessary when all required criteria are met.

    Standard covered indication

    • Gestational age: The infant is term or near-term and was born at least 34 weeks' gestation.≥34 weeks at birth
    • Clinical indication

      • Hypoxic respiratory failure: The infant has hypoxic respiratory failure.
      • Persistent pulmonary hypertension: The infant has echocardiographic evidence of persistent pulmonary hypertension of the newborn.
    • Congenital diaphragmatic hernia exclusion: The infant does not have congenital diaphragmatic hernia.Absent
    • Conventional treatment failure: The infant has failed conventional treatments, such as mechanical ventilation.Failure of conventional treatment
    Postoperative bridge therapy: In the postoperative management of pulmonary hypertension associated with heart or lung surgery in infants, iNO is a clinically accepted option and is covered as bridge therapy during the acute recovery phase.Acute recovery phase

    Stated postoperative covered use.

    Unproven, not medically necessary, or investigational use

    Not medically necessary or investigational for populations outside the covered indication.

    Noncovered populations

    • Preterm newborn: The newborn was born at less than 34 weeks' gestation.<34 weeks at birth
    • Congenital diaphragmatic hernia: The newborn has congenital diaphragmatic hernia.Present
    • Outside infancy: The individual is outside the infancy age group.Beyond the first year of life

      Use is experimental or investigational because there are no FDA-approved indications for this population.

    Congenital diaphragmatic hernia: iNO treatment for newborns with congenital diaphragmatic hernia is outside the standard covered indication and is considered unproven and not medically necessary.

    Use outside infancy: iNO treatment for individuals outside the infancy age group is excluded from covered FDA-approved use and is considered experimental or investigational because there are no FDA-approved indications for this population.

    Newborns born before 34 weeks' gestation: iNO is unproven and not medically necessary for preterm newborns born at less than 34 weeks' gestation.

    Other noncovered newborn uses: iNO is unproven and not medically necessary for newborns with congenital diaphragmatic hernia and for other newborn uses that fall outside the stated covered criteria, due to insufficient evidence of efficacy.

    Applicable Codes and Clinical Parameters

    Applicable Procedure CodesCPT
    94799Unlisted pulmonary service or procedure
    Gestational age at birth
    Minimum gestational ageAt least 34 weeks' gestation at birth
    Oxygenation index
    Oxygenation indexExceeds 25
    Initial iNO concentration
    Initial concentration20 ppm

    Treatment and Coverage Risk Considerations

    Step Therapy

    Document failure of conventional treatment

    Before using iNO for standard covered treatment, document that the infant has failed conventional treatments, such as mechanical ventilation.

    Denial Risk

    Confirm covered neonatal criteria

    Coverage may be denied when the infant was born before 34 weeks’ gestation, has congenital diaphragmatic hernia, or has not failed conventional treatments such as mechanical ventilation.

    • Confirm gestational age at birth is at least 34 weeks.
    • Document absence of congenital diaphragmatic hernia.
    • Document failure of conventional treatments, such as mechanical ventilation.

    Clinical Background

    Inhaled nitric oxide (iNO) is a gaseous pulmonary vasodilator that dilates blood vessels in ventilated regions of the lungs and decreases pulmonary vascular resistance. In selected newborns with hypoxic respiratory failure or persistent pulmonary hypertension of the newborn, it may improve oxygenation and reduce the need for extracorporeal membrane oxygenation. Potential harms include increased methemoglobin levels and an association with increased childhood cancer risk; benefits and risks should be weighed for each covered use.

    Policy Definitions

    Definition
    InfancyThe period from birth through the first year of life
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyInhaled Nitric Oxide Therapy (for Idaho Only)
    Policy CodePolicy CS173ID.C
    Change TypeSupporting information and references update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionConfirm that the infant has failed conventional treatment, such as mechanical ventilation, before using iNO.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaApplicable Codes and Clinical ParametersTreatment and Coverage Risk ConsiderationsClinical BackgroundPolicy Definitions
    Other newborn use: Any other newborn use that does not meet the covered criteria is unproven and not medically necessary due to insufficient evidence of efficacy.Does not meet covered criteria
    Denial Risk

    Avoid use outside infancy

    iNO treatment outside the infancy age group is considered experimental or investigational because there are no U.S. Food and Drug Administration-approved indications for this population.